COVID-19: Risk for Cytokine Targeting in Chronic Inflammatory Diseases?

Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.

Abstract

COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as these diseases are characterized by an intrinsic immune dysfunction leading to inflammation that may enhance risk for severe infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / immunology
  • Cytokines / antagonists & inhibitors*
  • Cytokines / immunology
  • Humans
  • Immune System Diseases / complications*
  • Inflammation / complications
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / immunology

Substances

  • Cytokines

Supplementary concepts

  • COVID-19